SCB-1022 not checked
Clover Biopharmaceuticals AUS Pty
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SCB-1022 (combination recombinant RSV-hMPV vaccine candidate) consists of three recombinant protein subunit antigens: RSV A strain (SCB-1019T(A)), RSV B strain (SCB-1019T(B)), and hMPV (SCB-1021).”In the company’s words, NCT06984094 on ClinicalTrials.gov
- Tested for
- RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
- Main trialPhase 1/2
- “This phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Parts 1 and 2) or Placebo (Part 3).”In the company’s words, NCT06984094 on ClinicalTrials.gov
Other drugs for RSV Infection
- RSVPreF3 OA vaccineGSK · Phase 3
- Human interferon α1b InhalationKexing Biopharm Co., Ltd. · Phase 3
- ABRYSVOPfizer · Phase 3
- ZiresovirShanghai Ark Biopharmaceutical Co., Ltd. · Phase 2/3
- S-337395Shionogi · Phase 2
- ZelicapavirEnanta Pharmaceuticals, Inc · Phase 2
Coming up1
- Mar 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | Mar 2028 | Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026